lg100754 and diazepinylbenzoic-acid

lg100754 has been researched along with diazepinylbenzoic-acid* in 1 studies

Other Studies

1 other study(ies) available for lg100754 and diazepinylbenzoic-acid

ArticleYear
Antagonist-perturbation mechanism for activation function-2 fixed motifs: active conformation and docking mode of retinoid X receptor antagonists.
    Journal of computer-aided molecular design, 2017, Volume: 31, Issue:6

    HX531, which contains a dibenzodiazepine skeleton, is one of the first retinoid X receptor (RXR) antagonists. Functioning via RXR-PPARγ heterodimer, this compound is receiving a lot of attention as a therapeutic drug candidate for diabetic disease controlling differentiation of adipose tissue. However, the active conformation of HX531 for RXRs is not well established. In the present study, quantum mechanics calculations and molecular mechanical docking simulations were carried out to precisely study the docking mode of HX531 with the human RXRα ligand-binding domain, as well as to provide a new approach to drug design using a structure-based perspective. It was suggested that HX531, which has the R configuration for the bent dibenzodiazepine plane together with the equatorial configuration for the N-methyl group attached to the nitrogen atom in the seven-membered diazepine ring, is a typical activation function-2 (AF-2) fixed motif perturbation type antagonist, which destabilizes the formation of AF-2 fixed motifs. On the other hand, the docking simulations supported the experimental result that LG100754 is an RXR homodimer antagonist and an RXR heterodimer agonist.

    Topics: Amino Acid Motifs; Benzoates; Binding Sites; Biphenyl Compounds; Humans; Molecular Docking Simulation; PPAR gamma; Protein Binding; Protein Conformation; Protein Domains; Protein Multimerization; Quantum Theory; Retinoid X Receptors; Retinoids; Stereoisomerism; Structure-Activity Relationship; Tetrahydronaphthalenes

2017